Investigation of the therapeutic effects of edaravone on acute cerebral infarction

Objective: Edaravone,a free radical scavenger approved for treatment of acute cerebral infarction(ACI);the purpose of the present study was to evaluate its efficacy including investigating sequential changes in serum concentrations of malondialdehyde(MDA),superoxide dismutase(SOD),glutathione peroxides(GSH-Px) in patients with ACI.Method: Within an open trial design,200 subjects with ACI received either 60~30mg(105 subjects) of edaravone via intravenous drip or routine treatment(95 subjects).10 days of administration was followed by a two-week observation period and the efficacy was evaluated by European stroke scales(ESS).Results: ESS score of the 11th and 15th day after treatment was markedly raised than that before(p0.01),the serum MDA level was decreased on the 4th 7th 11th 15th day after treatment(p0.01),and the concentration of SOD,GSH-Px were raised respectively(p0.01).Conclusion: Data from the present study suggest that edaravone is safe and may reduce the disablement rate of ACI by reducing MDA level and increasing the concentration of SOD and GSH-Px.